Drug intelligence / Profile preview

RI-OR2-TAT

Development stage: Preclinical
Lead developer: Lancaster University
Modality: Peptides
Administration: Intraperitoneal

Overview

RI-OR2-TAT is a brain-penetrant, proteolytically stable retro-inverso peptide inhibitor designed for the treatment of Alzheimer's disease. It is a chimeric peptide consisting of RI-OR2 (a retro-inverted version of the Aβ(16–20) KLVFF sequence) and a retro-inverted HIV-1 TAT protein transduction domain. The peptide is designed to cross the blood-brain barrier and bind to Amyloid-beta (Aβ) monomers, oligomers, and fibrils, thereby inhibiting the formation of toxic Aβ species. Preclinical studies in mouse models have demonstrated that RI-OR2-TAT reduces amyloid plaque load, decreases neuroinflammation and oxidative stress, and promotes neurogenesis in the brain.

Other names: Ac-rGffvlkGrrrrqrrkkrGy-NH2Ac-rGffvlkGrrrrqrrkkrGy-NH-2Ac-rGffvlkGrrrrqrrkkrGy-NH 2

Targets

Aβ42 (Amyloid-beta peptide 42)

Beyond the preview

Go deeper on RI-OR2-TAT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RI-OR2-TAT.

Explore the full profile